Table 1. Baseline Characteristics (N = 198)

Each level appears in a separate row; demographic, clinical, and treatment details.

Domain	Variable	Categories / Statistics	N (%) or Mean ± SD
Demographics	Age (years)	Mean ± SD (range)	58.4 ± 20.8 (18–97)
	Gender	Male	104 (52.5%)
		Female	94 (47.5%)
	Weight (kg)	Mean ± SD (range)	70.0 ± 20.2 (6–140)
Antibiotic exposure	Antibiotics within prior 90 days	Yes	182 (91.9%)
		No	16 (8.1%)
	Number of prior antibiotics	Median (IQR), range	4 (3–5), range 1–10
Comorbidities	Diabetes	Yes	104 (52.5%)
		No	94 (47.5%)
	Immunosuppression	Yes	162 (81.8%)
		No	36 (18.2%)
	Renal disease	Yes	72 (36.4%)
		No	126 (63.6%)
Clinical data	CDI severity	Severe	122 (61.6%)
		Non-severe	76 (38.4%)
	Abdominal pain at diagnosis	Yes	176 (88.9%)
		No	22 (11.1%)
	Fever (°C)	Mean ± SD (range)	37.4 ± 0.5 (37–39.5)
	WBC category	>15000	114 (57.6%)
		≤15000	84 (42.4%)
	Serum creatinine (mg/dL)	<1.5	106 (53.5%)
		≥1.5	92 (46.5%)
Treatment characteristics	Initial vancomycin dose	125 mg	93 (47.0%)
		250 mg	48 (24.2%)
		500 mg	57 (28.8%)
	Dose changed during course	Yes	34 (17.2%)
		No	164 (82.8%)
	Changed to dose*	125 mg	69 (34.8%)
		250 mg	59 (29.8%)
		500 mg	70 (35.4%)
	Dosing frequency	q6h	176 (88.9%)

Domain	Variable	Categories / Statistics	N (%) or Mean ± SD
		q8h	20 (10.1%)
		q12h	2 (1.0%)
	Planned duration	10 days	134 (67.7%)
		7 days	50 (25.3%)
		14 days	14 (7.1%)
	Route	Oral	198 (100%)
	Compliance ≥80%	Yes	180 (90.9%)
		No	18 (9.1%)
Concomitant therapy	Adjunct therapy (Metronidazole / Fidaxomicin)	Metronidazole	124 (62.6%)
		None	74 (37.4%)
	Probiotics	No	198 (100%)
	FMT	No	198 (100%)
	Other antibiotics during CDI treatment	Yes	178 (89.9%)
		No	20 (10.1%)
	Other antibiotics after CDI treatment	Yes	102 (51.5%)
		No	96 (48.5%)
Outcomes	Time to symptom resolution (days)	Day 3	80 (40.4%)
		Day 7	108 (54.5%)
		Day 10	6 (3.0%)
		Day 14	3 (1.5%)
			1 (0.5%)
	CDI recurrence (90 days)	Yes	0 (0%)
		No	198 (100%)
	Mortality (90 days)	Yes	58 (29.3%)
		No	140 (70.7%)
	Adverse events	None	198 (100%)

Table 2A. Continuous Variables by Vancomycin Dose

Mean ± SD and median [IQR]; Kruskal–Wallis test for p-values.

Variable	125 mg	250 mg	500 mg	Overall	P-value
Age (years)	59.98 ± 19.70; 62.0 [45.0, 75.0] (n=93)	59.27 ± 19.33; 58.0 [41.2, 76.0] (n=48)	55.05 ± 23.42; 58.0 [34.0, 75.0] (n=57)	58.39 ± 20.76; 58.0 [42.0, 76.0] (n=198)	0.5291
Weight (kg)	72.47 ± 20.93; 70.0 [60.0, 85.0] (n=93)	70.12 ± 16.73; 68.5 [58.0, 80.0] (n=48)	65.92 ± 21.31; 66.0 [55.0, 80.0] (n=57)	70.02 ± 20.20; 70.0 [58.0, 80.0] (n=198)	0.2132

Variable	125 mg	250 mg	500 mg	Overall	P-value
Ttr Days	5.87 ± 2.05; 7.0 [3.0, 7.0] (n=92)	5.46 ± 2.67; 7.0 [3.0, 7.0] (n=48)	5.19 ± 2.48; 3.0 [3.0, 7.0] (n=57)	5.57 ± 2.35; 7.0 [3.0, 7.0] (n=197)	0.0820

Table 2B. Categorical Variables by Vancomycin Dose

Domain and variable with each category on its own row; n (%), χ^2 or Fisher tests.

Domain	Variable	Level	125 mg	250 mg	500 mg	Overall	P-value
Demographics	Gender	Female	49 (52.7%)	24 (50.0%)	21 (36.8%)	94 (47.5%)	0.1556
		Male	44 (47.3%)	24 (50.0%)	36 (63.2%)	104 (52.5%)	
Antibiotic exposure	Antibiotics within prior 90 days	Yes	85 (91.4%)	44 (91.7%)	53 (93.0%)	182 (91.9%)	0.9500
		No	8 (8.6%)	4 (8.3%)	4 (7.0%)	16 (8.1%)	
Comorbidities	Diabetes	No	46 (49.5%)	23 (47.9%)	25 (43.9%)	94 (47.5%)	0.7986
		Yes	47 (50.5%)	25 (52.1%)	32 (56.1%)	104 (52.5%)	
	Immunosuppression	No	15 (16.1%)	12 (25.0%)	9 (15.8%)	36 (18.2%)	0.3711
		Yes	78 (83.9%)	36 (75.0%)	48 (84.2%)	162 (81.8%)	
	Renal disease	No	59 (63.4%)	30 (62.5%)	37 (64.9%)	126 (63.6%)	0.9664
		Yes	34 (36.6%)	18 (37.5%)	20 (35.1%)	72 (36.4%)	
Clinical data	CDI severity	Non-severe	38 (40.9%)	18 (37.5%)	20 (35.1%)	76 (38.4%)	0.7990
		Severe	55 (59.1%)	30 (62.5%)	37 (64.9%)	122 (61.6%)	
	Abdominal pain at diagnosis	No	9 (9.7%)	8 (16.7%)	5 (8.8%)	22 (11.1%)	0.4920
		Yes	84 (90.3%)	40 (83.3%)	52 (91.2%)	176 (88.9%)	
	WBC category	≤15000	32 (34.4%)	24 (50.0%)	28 (49.1%)	84 (42.4%)	0.0992
		>15000	61 (65.6%)	24 (50.0%)	29 (50.9%)	114 (57.6%)	
	Serum creatinine (mg/dL)	<1.5	45 (48.4%)	29 (60.4%)	32 (56.1%)	106 (53.5%)	0.3570
		≥1.5	48 (51.6%)	19 (39.6%)	25 (43.9%)	92 (46.5%)	

Domain	Variable	Level	125 mg	250 mg	500 mg	Overall	P-value
Treatment characteristics	Vancomycin changed during course	Yes	26 (28.0%)	2 (4.2%)	6 (10.5%)	34 (17.2%)	<0.001
		No	67 (72.0%)	46 (95.8%)	51 (89.5%)	164 (82.8%)	
	Changed to dose*	125 mg	28 (30.1%)	8 (16.7%)	12 (21.1%)	69 (34.8%)	0.1200
		250 mg	30 (32.3%)	16 (33.3%)	13 (22.8%)	59 (29.8%)	
		500 mg	35 (37.6%)	24 (50.0%)	32 (56.1%)	70 (35.4%)	
	Dosing frequency	q6h	82 (88.2%)	42 (87.5%)	52 (91.2%)	176 (88.9%)	0.8120
		q8h	9 (9.7%)	6 (12.5%)	5 (8.8%)	20 (10.1%)	
		q12h	2 (2.1%)	0 (0%)	0 (0%)	2 (1.0%)	
	Planned duration	10 days	73 (78.5%)	32 (66.7%)	29 (50.9%)	134 (67.7%)	0.0061
		7 days	14 (15.1%)	12 (25.0%)	24 (42.1%)	50 (25.3%)	
		14 days	6 (6.5%)	4 (8.3%)	4 (7.0%)	14 (7.1%)	
	Route	Oral	93 (100%)	48 (100%)	57 (100%)	198 (100%)	—
	Compliance ≥80%	Yes	84 (90.3%)	44 (91.7%)	52 (91.2%)	180 (90.9%)	0.9600
		No	9 (9.7%)	4 (8.3%)	5 (8.8%)	18 (9.1%)	
Concomitant therapy	Adjunct therapy (Metronidazole / Fidaxomicin)	Yes	56 (60.2%)	32 (66.7%)	36 (63.2%)	124 (62.6%)	0.7200
		No	37 (39.8%)	16 (33.3%)	21 (36.8%)	74 (37.4%)	
	Probiotics	No	93 (100%)	48 (100%)	57 (100%)	198 (100%)	—
	FMT	No	93 (100%)	48 (100%)	57 (100%)	198 (100%)	—
	Other antibiotics during CDI	Yes	83 (89.2%)	42 (87.5%)	53 (93.0%)	178 (89.9%)	0.7110
		No	10 (10.8%)	6 (12.5%)	4 (7.0%)	20 (10.1%)	
	Other antibiotics after CDI	Yes	46 (49.5%)	26 (54.2%)	30 (52.6%)	102 (51.5%)	0.9000
		No	47 (50.5%)	22 (45.8%)	27 (47.4%)	96 (48.5%)	

Domain	Variable	Level	125 mg	250 mg	500 mg	Overall	P-value
Outcomes	90-day recurrence	Yes	0 (0%)	0 (0%)	0 (0%)	0 (0%)	—
		No	93 (100%)	48 (100%)	57 (100%)	198 (100%)	
	90-day mortality	Yes	26 (28.0%)	15 (31.2%)	17 (29.8%)	58 (29.3%)	0.9155
		No	67 (72.0%)	33 (68.8%)	40 (70.2%)	140 (70.7%)	
	Adverse events	None	93 (100%)	48 (100%)	57 (100%)	198 (100%)	—

Table 3. Outcomes by Vancomycin Dose

Clinical outcomes including mortality and recurrence across dose groups.

dose	MORT90 %	RECURRENCE %	ADVERSE %
125.0	28.000	0.0	0.0
250.0	31.200	0.0	0.0
500.0	29.800	0.0	0.0
Overall	29.293	0.0	0.0

Table 4. Time-to-Resolution by Dose

Distribution of resolution days (% patients) across doses.

dose	Resolution day	125.0	250.0	500.0
	3	31.5	45.8	50.9
	7	64.1	50.0	43.9
	10	4.3	0.0	3.5
	14	0.0	4.2	1.8

Table 5. Logistic Regression (90-day Mortality)

Adjusted odds ratios (OR); bold = significant ($p < 0.05$).

Variable	OR	CI Lower	CI Upper	p-value
Intercept	0.000000e+00	0.000	inf	1.000
C(dose)[T.250]	1.234000e+00	0.403	3.781	0.712
C(dose)[T.500]	1.200000e+00	0.400	3.599	0.745
C(gender)[T.M]	1.482000e+00	0.578	3.805	0.413
C(diabetes_b)[T.Yes]	9.060000e-01	0.320	2.565	0.852
C(immuno_b)[T.Yes]	2.717000e+00	0.581	12.694	0.204

Variable	OR	CI Lower	CI Upper	p-value
C(severity)[T.Severe]	1.133000e+00	0.172	7.471	0.897
C(wbc_cat)[T.>15000]	1.964000e+00	0.535	7.216	0.309
C(scr_binary)[T.Low (<1.5)]	2.980000e-01	0.082	1.087	0.067
C(dose_changed)[T.Yes]	1.117000e+00	0.343	3.635	0.855
C(compliant)[T.Yes]	1.020000e-01	0.022	0.476	0.004
C(abx_during)[T.Yes]	5.320320e+11	0.000	inf	1.000
C(abx_after)[T.Yes]	4.500000e-02	0.016	0.130	0.000
C(adjunct)[T.No]	1.650000e-01	0.054	0.505	0.002
age	1.017000e+00	0.989	1.047	0.240

Table 6. Cox PH (Time-to-Resolution)

Adjusted hazard ratios (HR); bold = significant ($p < 0.05$).

Variable	HR	CI Lower	CI Upper	p-value
age	1.000	0.992	1.008	0.913
dose_250	1.123	0.767	1.645	0.550
dose_500	1.093	0.764	1.562	0.628
gender_M	1.471	1.088	1.989	0.012
diabetes_b_Yes	0.787	0.559	1.108	0.170
immuno_b_Yes	1.151	0.741	1.787	0.532
severity_Severe	0.866	0.471	1.592	0.642
wbc_cat_>15000	0.872	0.538	1.413	0.578
scr_binary_Low (<1.5)	1.065	0.683	1.659	0.782
dose_changed_Yes	0.764	0.512	1.140	0.187
compliant_Yes	0.462	0.253	0.845	0.012
abx_during_Yes	2.114	1.188	3.763	0.011
abx_after_Yes	0.873	0.645	1.181	0.379
adjunct_No	1.088	0.772	1.532	0.631

Figa Km By Dose



Figb Ttr Stacked By Dose



Figc Mortality By Dose



Figd Adverse By Dose



Fige1 Hist Age



Fige2 Hist Weight



Fige3 Hist Ttr



Figf Logit Or Forest

Figg Cox Hr Forest


Cox PH: Time to Resolution (Hazard Ratios)
adjunct_No
abx_after_Yes
abx_during_Yes
compliant_Yes
dose_changed_Yes
scr_binary_Low (<1.5)
wbc_cat_>15000
severity_Severe
immuno_b_Yes
diabetes_b_Yes
gender_M
dose_500
dose_250
age
10^0
Hazard Ratio (log scale)